Precision Medicine in Oncology® | Specialty

Taking a Multidisciplinary Approach to mCRC Care

February 12th 2016

Patient-Derived Xenografts Could Improve Precision Medicine Outcomes

February 6th 2016

Researchers at the UC Davis Comprehensive Cancer Center are personalizing treatment using tumor xenografts in mice to test and identify more precise treatments for bladder cancer patients.

Osimertinib Approved in Europe for EGFR T790M-Mutant NSCLC

February 3rd 2016

The European Commission has granted a conditional marketing authorization to osimertinib for patients with locally advanced or metastatic EGFR T790M mutation-positive non–small cell lung cancer, regardless of prior treatment with EGFR TKI.

Dr. Ingrid Mayer on Targeted Therapies in ER+ Breast Cancer

February 3rd 2016

Ingrid A. Mayer, MD, co-leader and Clinical Director, Breast Cancer Research Program Chair, Data and Safety Monitoring Committee, Associate Professor of Medicine (Hematology/Oncology), medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the use of targeted therapies in estrogen-receptor (ER)-positive breast cancer.

Medical World News: Precision Medicine in Oncology

February 2nd 2016

Expression of the apoptosis regulator protein BIM could help predict response to PD-1 blockade in patients with melanoma.

Is PD-L1 Just the Tip of the Iceberg?

February 1st 2016

PD-1 and PD-L1 inhibition offers the possibility for precision immuno-oncology through the application of biomarkers that predict the immune systems response. This principle has been demonstrated by two of the most recent FDA approvals for patients with lung cancer.

Olaparib Studies Put Focus on BRCA-Positive Breast Cancers

January 30th 2016

The identification of the BRCA1 and BRCA2 tumor suppressor genes and the recognition that inherited loss of function (deleterious) mutations in one of these important genes places women at high risk for the development of breast, ovarian, and other cancers are major advances in women’s health research.

Genome Sequencing Hints at New Targets for Cervical Cancer

January 14th 2016

With technological advancements in genome sequencing, researchers are now gaining a more detailed picture of the genetic drivers of cervical cancer and the important role that the human papillomavirus, responsible for the vast majority of cervical cancer cases, plays in molding the genetic profile of this disease.

Emerging Targets in NSCLC Treatment

January 13th 2016

Subtypes in NSCLC: BRAF and RET

January 13th 2016

Approval of Third-Generation TKIs for EGFR-Targeted Therapies

January 13th 2016

Next-Generation ALK Inhibitors for NSCLC

January 13th 2016

Ceritinib in Crizotinib-Resistant NSCLC

January 13th 2016

Crizotinib for ALK-Rearranged NSCLC

January 13th 2016

EGFR Inhibition and Resistance Mechanisms

January 13th 2016

Current Practices in NSCLC Genetic Testing

January 13th 2016

Therapeutic Classes in Advanced NSCLC

January 13th 2016

Dr. Steven Rosenberg on the Curative Potential of Adoptive Cell Therapy

January 8th 2016

Steven A. Rosenberg, MD, PhD, chief, Surgery Branch, senior investigator, head, Tumor Immunology Section, National Cancer Institute, explains advancements in adoptive cell therapy for the treatment of melanoma.

Fresh Approaches and Open Minds Needed to Assess Unique Targeted Therapy Outcomes

January 8th 2016

There is an objectively rational and scientifically valid alternative to evaluate N-of-1 experiences, and there is a critical need for the continued development of such approaches, which the oncology community increasingly recognizes as a necessary step to replace the established but untenable randomized clinical trial paradigm.

Compatibility Check: Can Precision Medicine and Pathways Co-Exist?

December 23rd 2015

One of the most widely talked about trends in healthcare is precision medicine, which uses detailed genetic information about a patient’s cancer to more precisely treat the disease, effectively targeting the tumor. This heightened awareness raises an important question: are precision medicine and pathways compatible?